Integrated Advisors Network LLC Invests $4.73 Million in TransMedics Group, Inc. $TMDX

Integrated Advisors Network LLC acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 47,590 shares of the company’s stock, valued at approximately $4,731,000. Integrated Advisors Network LLC owned about 0.14% of TransMedics Group at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of TMDX. Harvest Fund Management Co. Ltd bought a new position in TransMedics Group during the third quarter valued at approximately $29,000. Allworth Financial LP boosted its stake in shares of TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares in the last quarter. Parallel Advisors LLC boosted its stake in shares of TransMedics Group by 42.1% in the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after purchasing an additional 83 shares in the last quarter. Ascentis Independent Advisors bought a new position in shares of TransMedics Group during the 1st quarter valued at $30,000. Finally, North Star Investment Management Corp. bought a new position in shares of TransMedics Group during the 1st quarter valued at $30,000. Institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on TMDX shares. Stifel Nicolaus lifted their target price on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, June 18th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of TransMedics Group in a research note on Tuesday, June 9th. TD Cowen reiterated a “buy” rating and issued a $120.00 price objective on shares of TransMedics Group in a report on Wednesday, July 1st. UBS Group reiterated a “hold” rating on shares of TransMedics Group in a report on Tuesday, May 26th. Finally, Needham & Company LLC lowered their target price on TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Six research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $134.50.

Insider Buying and Selling at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the transaction, the director directly owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 6.90% of the company’s stock.

TransMedics Group Trading Down 3.0%

Shares of TransMedics Group stock traded down $2.11 during trading on Tuesday, reaching $69.12. 247,539 shares of the stock were exchanged, compared to its average volume of 1,103,368. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. The firm has a market cap of $2.39 billion, a price-to-earnings ratio of 15.75 and a beta of 1.89. TransMedics Group, Inc. has a 1 year low of $60.10 and a 1 year high of $156.00. The stock’s fifty day moving average is $74.20 and its 200 day moving average is $107.75.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The business had revenue of $173.93 million for the quarter, compared to analysts’ expectations of $174.44 million. TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The firm’s revenue for the quarter was up 21.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.70 EPS. As a group, equities research analysts expect that TransMedics Group, Inc. will post 1.92 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.